Related Experiment Video
Updated: Jan 9, 2026

Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics
Published on: March 15, 2024
SUCLA2 Inhibited Lysine Succinylation of SHMT2 to Suppress Ferroptosis and Renal Interstitial Fibrosis
Huiyan Lyu1, Donghua Hou2, Yadong Liu3
1Department of Nephrology, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang Province, P.R. China.
Abstract:
Renal interstitial fibrosis (RIF) is a common pathway to end-stage renal diseases progressing towards renal failure. Angiotensin II (Ang II), as the core effector molecule of the renin-angiotensin system (RAS), is widely recognized as a key factor promoting RIF. Succinyl-CoA ligase subunit-beta (SUCLA2) can reversibly convert succinyl CoA into succinate and participates in many biological processes. This research was designed to explore the roles and mechanisms of SUCLA2 in RIF. Ang II-induced mouse model and HK-2 cell model were established. Ang II induced significant histological damage and interstitial fibrosis in mouse kidneys. SUCLA2 mRNA and protein levels were decreased, but lysine succinylation levels were increased in renal tissues of Ang II-induced mice and Ang II-treated HK-2 cells. Overexpression of SUCLA2 inhibited Ang II-induced ferroptosis, along with decreased lysine succinylation and succinyl-CoA levels. SUCLA2 negatively regulated lysine succinylation of SHMT2. Furthermore, SHMT2 desuccinylation by sirtuin 5 (SIRT5) inhibited Ang II-induced ferroptosis, and the inhibitory effect of SUCLA2 overexpression on Ang II-induced ferroptosis was restored by SHMT2 silencing. In vivo, the delivery of adeno-associated virus-mediated SUCLA2-expressing vector into mouse kidneys alleviated Ang II-induced histological damage and interstitial fibrosis. Our research has revealed SUCLA2 inhibited lysine succinylation of SHMT2 to repress renal cell ferroptosis and interstitial fibrosis.
Insights
Succinyl-CoA ligase subunit-beta (SUCLA2) protects against renal interstitial fibrosis (RIF) by inhibiting ferroptosis. SUCLA2 reduces lysine succinylation of SHMT2, thereby mitigating kidney damage and fibrosis.
Area of Science:
- Biochemistry
- Nephrology
- Molecular Biology
Background:
- Renal interstitial fibrosis (RIF) is a major cause of end-stage renal disease.
- Angiotensin II (Ang II) is a key mediator promoting RIF.
- The role of Succinyl-CoA ligase subunit-beta (SUCLA2) in RIF remains unclear.
Purpose of the Study:
- To investigate the role and mechanism of SUCLA2 in Ang II-induced RIF.
- To explore the relationship between SUCLA2, lysine succinylation, and ferroptosis in RIF.
- To assess the therapeutic potential of SUCLA2 in RIF.
Main Methods:
- Established Ang II-induced mouse and HK-2 cell models of RIF.
- Assessed SUCLA2 expression and lysine succinylation levels.
- Utilized SUCLA2 overexpression and SHMT2 silencing techniques.
- Administered adeno-associated virus-mediated SUCLA2 vectors in vivo.
Main Results:
- Ang II reduced SUCLA2 levels and increased lysine succinylation in renal tissues.
- SUCLA2 overexpression suppressed Ang II-induced ferroptosis and decreased SHMT2 succinylation.
- SHMT2 desuccinylation by SIRT5 inhibited ferroptosis; SUCLA2's effect was dependent on SHMT2.
- In vivo delivery of SUCLA2 alleviated RIF in mice.
Conclusions:
- SUCLA2 acts as a protective factor against RIF.
- SUCLA2 inhibits renal cell ferroptosis and interstitial fibrosis by reducing SHMT2 lysine succinylation.
- SUCLA2 represents a potential therapeutic target for RIF.

